Abstract
The pathogenesis of inflammatory bowel disease (IBD) is complicated and even several therapeutic strategies have been developed, they are not adequate for achieving mucosal remission in all IBD patients. Several reports have described the role of carbon monoxide (CO) in protection against chronic intestinal inflammation. CO has recently emerged as a potent immunomodulatory entity, anti-inflammatory agent, and homeostasis of physiological condition. CO reduces lipopolysaccharide-induced proinflammatory cytokines in macrophages via the effect of MAPK pathways. Interleukin-6, one of the important cytokines in the pathogenesis of IBD is also regulated by CO. Epithelial cell restitution is reported to be important factor to control IBD and CO has been reported to enhance colonic epithelial restitution through FGF15/19 expression in colonic myofibroblasts. CO also reduced mucosal damage and inflammation in several experimental animal colitis models such as interleukin-10-/- mouse model, TCRα-/- mouse model, dextran sodium sulfate colitis model, and trinitrobennzen sulfonic acid colitis model. Taken together, CO has anti-inflammatory and enhancement of restitution examined in vitro model and in vivo experimental colitis model. These results indicate that CO may have a potential to be one of the therapeutic strategies in IBD patients.
Keywords: Carbon monoxide, cytokine, inflammatory bowel disease, macrophage, restitution, Epithelial cell, trinitrobennzen, anti-inflammatory, pathogenesis, intestinal inflammation
Current Medicinal Chemistry
Title: Therapeutic Potential of Carbon Monoxide (CO) for Intestinal Inflammation
Volume: 19 Issue: 1
Author(s): Y. Naito, K. Uchiyama, T. Takagi and T. Yoshikawa
Affiliation:
Keywords: Carbon monoxide, cytokine, inflammatory bowel disease, macrophage, restitution, Epithelial cell, trinitrobennzen, anti-inflammatory, pathogenesis, intestinal inflammation
Abstract: The pathogenesis of inflammatory bowel disease (IBD) is complicated and even several therapeutic strategies have been developed, they are not adequate for achieving mucosal remission in all IBD patients. Several reports have described the role of carbon monoxide (CO) in protection against chronic intestinal inflammation. CO has recently emerged as a potent immunomodulatory entity, anti-inflammatory agent, and homeostasis of physiological condition. CO reduces lipopolysaccharide-induced proinflammatory cytokines in macrophages via the effect of MAPK pathways. Interleukin-6, one of the important cytokines in the pathogenesis of IBD is also regulated by CO. Epithelial cell restitution is reported to be important factor to control IBD and CO has been reported to enhance colonic epithelial restitution through FGF15/19 expression in colonic myofibroblasts. CO also reduced mucosal damage and inflammation in several experimental animal colitis models such as interleukin-10-/- mouse model, TCRα-/- mouse model, dextran sodium sulfate colitis model, and trinitrobennzen sulfonic acid colitis model. Taken together, CO has anti-inflammatory and enhancement of restitution examined in vitro model and in vivo experimental colitis model. These results indicate that CO may have a potential to be one of the therapeutic strategies in IBD patients.
Export Options
About this article
Cite this article as:
Naito Y., Uchiyama K., Takagi T. and Yoshikawa T., Therapeutic Potential of Carbon Monoxide (CO) for Intestinal Inflammation, Current Medicinal Chemistry 2012; 19 (1) . https://dx.doi.org/10.2174/092986712803413935
DOI https://dx.doi.org/10.2174/092986712803413935 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
Current advances in inherited cardiomyopathy
Describe in detail all novel advances in multimodality imaging related to inherited cardiomyopathy diagnosis and prognosis. Shed light to deeper phenotypic characterization. Acknowledge recent advances in genetics, genomics and precision medicineread more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Role of Nitric Oxide Signaling Pathways in Brain Injuries
Current Chemical Biology Synthesis and Evaluation of Glycyrrhetic Acid-aromatic Hybrids as Anti-inflammatory Agents
Medicinal Chemistry An Emerging Antiarrhythmic Target: Late Sodium Current
Current Pharmaceutical Design Gene Therapy in Cerebrovascular Diseases
Current Gene Therapy Functional Role of ADP-Ribosyl-Acceptor Hydrolase 3 in poly(ADPRibose) Polymerase-1 Response to Oxidative Stress
Current Protein & Peptide Science 4-Methylumbelliferones Analogues as Anticancer Agents: Synthesis and in Cell Pharmacological Studies
Anti-Cancer Agents in Medicinal Chemistry The Angiotensin Converting Enzyme 2 (ACE2), Gut Microbiota, and Cardiovascular Health
Protein & Peptide Letters Disruption of Circadian Rhythms and Sleep in Critical Illness: Potential Implications for Angiogenesis After Myocardial Infarction. A Review
Current Pharmaceutical Design Wip1-Deficient Neutrophils Significantly Promote Intestinal Ischemia/Reperfusion Injury in Mice
Current Molecular Medicine Ca2+ Signalling in Damaged Endothelium: Do Connexin Hemichannels Aid in Filling the Gap?
Current Drug Therapy Clinical Applications of Cardiac Multi-Slice Computed Tomography
Current Medical Imaging Catastrophic Antiphospholipid Syndrome: Lessons from the “CAPS Registry”
Current Rheumatology Reviews Sirtuin Modulators: Mechanisms and Potential Clinical Implications
Current Medicinal Chemistry Near Infrared Spectroscopy in Healthy Preterm and Term Newborns: Correlation with Gestational Age and Standard Monitoring Parameters
Current Neurovascular Research Cardiac (myo)fibroblast: Novel Strategies for its Targeting Following Myocardial Infarction
Current Pharmaceutical Design Ischemic Neuronal Damage
Current Pharmaceutical Design Abatacept and Glomerular Diseases: The Open Road for the Second Signal as a New Target is Settled Down
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Exercise and Cardiac Preconditioning Against Ischemia Reperfusion Injury
Current Cardiology Reviews Anti-inflammatory Effects of Dietary Antioxidants
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Patent Annotations
Recent Patents on Cardiovascular Drug Discovery